RAPid SimPLE Targeted Radiation Treatment for Brain Metastases
Key facts
- Who runs it
- British Columbia Cancer Agency
- Where
- Canada6 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 100 people, planned
- Started
- 1 Jul 2022
- Expected to end
- 30 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Targeting All Brain Metastases
- Record updated
- 21 September 2026
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Patients must fulfil all the following criteria to be eligible for admission to the study:
- Age ≥ 18
- Pathological diagnosis of a non-hematopoietic malignancy
- Brain metastases of any size
- Any number of untreated or progressing, previously treated brain metastases that can all be contoured and targeted
- Presence of extracranial disease
- Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) ≤ 2.0 (https://brainmetgpa.com/) or Graded Prognostic Assessment ≤ 2.0 (Appendix I)
- Able to complete the EuroQOL (EQ-5D-5L) questionnaire
- Willing and able to have regular imaging follow up
- Feasible to start protocol treatment within 14 calendar days of participant enrolment
- Karnofsky Performance Score (KPS) ≥ 50
Who cannot take part
- WBRT less than 3 months prior to randomization
- Neurologically declining despite corticosteroids
- Appropriate for surgery or stereotactic radiosurgery
- Disseminated leptomeningeal carcinomatosis (limited pachymeningeal disease is permitted)
- Systemic lupus erythematosis, scleroderma, or other connective tissue disorders not in remission
- Any other serious intercurrent illness or medical condition judged by the local investigator to compromise the patient's safety, preclude safe administration of the planned protocol treatment, or prevent the patient from being managed according to the protocol guidelines
- Patients who fulfill any of the following criteria are not eligible for admission to the study:
- Inability to have a brain MRI
- Multiple sclerosis
- Germ cell and primary brain tumours
- Pregnancy
- Potentially fertile men or women of childbearing potential who are unwilling to employ highly effective contraception
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of the study is to show that rapid, simple targeted radiotherapy to brain metastases with 8 Gy / 1 is non-inferior to 20 Gy / 5 in terms of overall survival for patients with poor prognosis.
The 2 groups in the trial
- 20 Gy in 5 Fractions Volumetric Modulated Arc Therapy to Brain MetastasesExisting treatment, for comparison
Five treatments of 4 Gy will be delivered using volumetric modulated arc therapy on a conventional linear accelerator in a conventional head shell without the use of stereotactic radiosurgery technique.
Treatment: Targeting All Brain Metastases
- 8 Gy in 1 Fraction Volumetric Modulated Arc Therapy to Brain MetastasesTreatment being tested
A single treatment of 8 Gy will be delivered using volumetric modulated arc therapy on a conventional linear accelerator in a conventional head shell without the use of stereotactic radiosurgery technique.
Treatment: Targeting All Brain Metastases
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Phase II Non-Inferiority Study of 5-Day Versus 1-Day RAPid SimPLE (RAPPLE) Targeted Radiation Treatment for Brain Metastases
- Record updated
- 21 September 2026